AbbVie (NYSE:ABBV | ABBV Price Prediction) stock has pulled back 12% over the past month, sliding to around $204. JPMorgan isn’t running from that weakness — it’s calling it a buying opportunity,…
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Coca-Cola (NYSE:KO) both closed out 2025 with Q4 earnings and have raised dividends for 63 consecutive years. But beneath that shared milestone sit…
It can be an appealing idea to replace your paycheck with passive income. While it sounds exciting on the surface, it is a slightly complicated task. You'll have to work backwards and…
With inflation back in the economic picture, simply getting a dependable income stream may not be the best strategy for Boomer and Gen X retirees. Without some degree of growth, portfolios built…
Markets have delivered plenty of twists lately, with inflation cooling but growth uneven and volatility still lurking around every earnings corner. Smart investors know one truth holds steady: reliable income beats hype…
Rich Duprey The VIX has climbed 41% in a single month, sitting at 26.95 and in the 93rd percentile of the past year’s readings. For retirement investors who felt last April’s volatility spike to…
VanEck Pharmaceutical ETF (NYSEARCA:PPH) exists to give investors broad exposure to the global pharmaceutical industry without the binary risk of betting on a single drug pipeline. Right now, that diversification is being…
Retirees and income-focused investors have long used Vanguard Value ETF (NYSEARCA:VTV) as a core portfolio anchor, drawn to its dividend income, lower volatility relative to growth funds, and near-zero cost structure. When…
Healthcare spending doesn’t stop during recessions. That structural reality is the core argument for owning Vanguard Health Care ETF (NYSEARCA:VHT), a pure-play sector fund that has quietly compounded wealth for long-term investors…
A 1.5% yield sounds unimpressive until you realize the dividend check doubles roughly every seven years. That is the premise behind the Vanguard Dividend Appreciation ETF (NYSEARCA:VIG): skip the high-yield traps and…
Half of every dollar invested in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) rides on just two companies pulling in opposite directions in 2026. With a 0.38% expense ratio, nearly $1.1 billion in net…
JPMorgan Dividend Leaders ETF (NYSEARCA:JDIV) launched in September 2024 with an appealing premise: a curated portfolio of global dividend leaders. The name implies income. The reality is a 1.59% yield at a…
Let’s cut through the noise on this dividend dream that keeps investors up at night. The key question many investors have is how much cash do you need parked in a portfolio to…
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) has been one of healthcare’s standout performers over the past year, with shares up 48% over the past 12 months and 16% year-to-date. The…
The stock market could face serious trouble as 2026 heads into the second quarter under duress. Extreme valuations collide with geopolitical tensions, AI investment skepticism, and policy headwinds. The Warren Buffett indicator…
